Sugi Predict

Sugi Predict / Compounds / SCHEMBL774179

SCHEMBL774179

SCHEMBL774179

CN(C)c1ccc(C(=O)CBr)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 9/20 0.61
▸ HPGD P15428 2/20 0.59
▸ MAPT P10636 2/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ PTPN1 P18031 5/20 0.57
▸ RAB9A P51151 3/20 0.52
▸ NPC1 O15118 3/20 0.52
▸ HTT P42858 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10001066 1.00 GSK3B (0.61) GSK3BHPGDMAPTALDH1A1PTPN1
SCHEMBL10001068 1.00 GSK3B (0.61) GSK3BHPGDMAPTALDH1A1PTPN1
SCHEMBL25424836 0.83 ALDH1A1 (0.64) HPGDMAPTALDH1A1RAB9ANPC1
SCHEMBL19130858 0.82 GSK3B (0.55) GSK3BMAPTALDH1A1PTPN1RAB9A
SCHEMBL16754090 0.82 GSK3B (0.55) GSK3BHPGDMAPTALDH1A1PTPN1
SCHEMBL702196 0.82 PTPN1 (0.62) GSK3BHPGDMAPTALDH1A1PTPN1
SCHEMBL29403777 0.82 PTPN1 (0.62) GSK3BHPGDMAPTALDH1A1PTPN1
SCHEMBL205280 0.82 GSK3B (0.80) GSK3BPTPN1RAB9ANPC1HDAC1
SCHEMBL303244 0.81 ALDH1A1 (0.61) HPGDMAPTALDH1A1RAB9ANPC1
SCHEMBL22367578 0.81 ALDH1A1 (0.61) HPGDMAPTALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098036-A1 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2026-04-09 — — US disclosed
US-12522594-B2 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2026-01-13 — — US disclosed
EP-4139286-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 — — EP disclosed
US-20240294505-A1 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-09-05 — — US disclosed
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 — — US disclosed
US-20230348394-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-02 — — US disclosed
US-20230348394-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-02 — — US disclosed
US-11795164-B2 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer BAYER AKTIENGESELLSCHAFT (DE) 2023-10-24 — — US disclosed
CN-116554152-A 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer 拜耳股份公司 2023-08-08 — — CN disclosed
CN-116531380-A 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer 拜耳股份公司 2023-08-04 — — CN disclosed
US-4814332-A PARASITICIDES HOFFMAN-LA ROCHE INC. (US) 1989-03-21 — — US disclosed
US-4808727-A CHEMICAL INTERMEDIATES FOR WATER-SOLUBLE SALTS OF PARASITICIDES HOFFMANN-LAROCHE INC. (US) 1989-02-28 — — US disclosed
EP-0167973-B1 REDOX INDICATORS Roche Diagnostics GmbH (DE) 1988-06-22 — — EP disclosed
EP-0266532-A1 1,3-Disubstituted imidazolium salts F. HOFFMANN-LA ROCHE AG (CH) 1988-05-11 — — EP disclosed
EP-0253084-A2 1,3-Disubstituted imidazolium salts F. HOFFMANN-LA ROCHE AG (CH) 1988-01-20 — — EP disclosed
EP-0200947-A1 1,3-Disubstituted imidazolium salts F. HOFFMANN-LA ROCHE AG (CH) 1986-11-12 — — EP disclosed
EP-0189472-A1 PYRIMIDINONE DERIVATIVES GLAXO GROUP LIMITED (GB) 1986-08-06 — — EP disclosed
WO-1986001205-A1 PYRIMIDINONE DERIVATIVES GLAXO GROUP LIMITED (GB) 1986-02-27 — — WO disclosed
EP-0167973-A1 Redox indicators Roche Diagnostics GmbH (DE) 1986-01-15 — — EP disclosed
US-4013692-A ANTIINFLAMMATORY, ANTIPYRETICS, ANALGESICS RIKER LABORATORIES, INC. (US) 1977-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098036-A1 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER AHR, CBR1, CNR1 GSK3B 2364/4885HPGD 1439/4885MAPT 4854/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG GSK3B 890/4885HPGD 2344/4885MAPT 3263/4885
US-20230348394-A1 COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES TNNC1, PYGM, GYS1 GSK3B 1773/4885HPGD 1935/4885MAPT 1996/4885
US-11795164-B2 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer AHR, ARNT, HRH2 GSK3B 2339/4885HPGD 120/4885MAPT 4802/4885
US-20240294505-A1 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER AHR, ARNT, HRH2 GSK3B 2301/4885HPGD 117/4885MAPT 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.